Pfizer seeks wider Xeljanz indication

Share this article:

Pfizer is looking to expand the indication for its RA drug Xeljanz. The drugmaker announced Monday that it plans to file an sNDA to expand the pill's label to include moderate-to-severe plaque psoriasis. The company expects to file the request for the twice-a-day medication early next year.

An expanded indication of this sort is not uncommon for Xeljanz's biologic counterparts, drugs such as AbbVie's Humira, whose indications include RA, plaque psoriasis and Crohn's disease. Amgen's RA shot Enbrel is also approved for plaque psoriasis and juvenile idiopathic arthritis, among other conditions.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.